Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Pfizer will maintain its 2025 financial forecasts ...